ZURICH, May 12 (Reuters) - Swiss drugmaker Roche ROPC.S has received the CE mark - a European regulatory clearance allowing sale in the region - for its second Elecsys blood test for Alzheimer's disease, it said on Tuesday.

The test was developed with U.S. company Eli Lilly LLY.N.

• Compared with its already approved pTau181 test, which mainly helps rule out Alzheimer's-related amyloid pathology, the newer pTau217 test can both help confirm and exclude the disease. It is validated for use in both primary and specialist care.

• The test has already received breakthrough device designation from the U.S. FDA.

• Blood tests could speed diagnosis and widen access to treatments such as Biogen BIIB.O and Eisai's 4523.T Leqembi and Eli Lilly's Kisunla, as current diagnostic methods are often costly or uncomfortable.

• Roche said an estimated 75% of people living with dementia remain undiagnosed.

• The test is expected to become available in CE-marked markets from July, Olivier Gillieron, life cycle leader in cardiometabolic and neurology at Roche told media in a call.